Improved Device Programming Reduces Inappropriate Therapy and Risk of Death for Implantable Defibrillator Patients (via PR Newswire)
NATICK, Mass., Nov. 6, 2012 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) clinical trial that demonstrated…
published: November 9, 2012 in: Boston Scientific, Cardio, Clinical Studies/Trials, Congresses and Meetings